Kelso Pharma

Kelso Pharma is a London-based, private specialty pharma company building a portfolio of branded medicines in oncology and rare diseases for the European market. Founded in 2016 and backed by Apposite Capital, the company grows through strategic acquisitions, partnerships, and organic expansion, as evidenced by its recent rebranding of Velit Biopharma in Italy. Led by an experienced team, Kelso focuses on commercial-stage assets that offer improved patient compliance and supply security, positioning itself as a value-added provider within cost-conscious healthcare systems.

Commercial platform focused on acquiring, partnering, and commercializing late-stage or approved niche and complex specialty medicines, with an emphasis on improving patient compliance and supply chain security.

Kelso competes with other specialty pharma acquirers and mid-sized pharma companies seeking to bolster their European portfolios. It also competes with the originator companies of the products it targets for acquisition. Its key differentiators are its focused European commercial expertise, nimble operational structure, and backing from a dedicated healthcare private equity firm.